No improvement seen in two-year progression-free survival for radiotherapy with durvalumab versus radiotherapy with cetuximab

Hazard ratio for dementia higher in those with stroke compared with reference population, those with acute myocardial infarction

Rates among servicemen also lower for regional and distant metastases

Increased odds ratio seen for asthma onset with high exposure to butylparaben; risk associated with 4-nonylphenol varies by gender

Itacitinib results in low cytokine release syndrome grades, low incidence of acute, chronic graft versus host disease

Noninferiority of reduced-dose anticoagulants could not be proven in patients with VTE who need extended anticoagulation

More recent cohorts also have lower levels of fasting triglycerides, but higher levels of fasting glucose

Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone

Finding seen for adults with overweight or obesity and either employer-sponsored insurance or Medicare coverage

Meta-analysis shows significant reductions in composite kidney outcome, kidney failure, MACE, all-cause death